Oncolytics Biotech Inc ONCY

New Press Release - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer studyTogether, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast...read article.

[canadafan]

Looks to be great news. I hope a few shorts suffer today. i don't need to name names. i hold a lot if shares. there are those on here who name call & provide nothing but conjecture. all tye while admitting zero ownership. The positivec Bracelrt reukts can now be used ( in conjection with the on- going IREN study) & upcoming pancreatic cance4 phase 3....Onc is well resdy to tango. stay

[CMHarring218431]

Finally.....Very Nice! Nasdaq pre-market 18,000 shares.

[13X2413]

Hope I'm wrong. Pre-market looks very disappointing?? 

[13X2413]

Starting to build a little. Please, please, please!!

[13X2413]

What a freakin' joke. Markets up, allegedly good news that people have been waiting for and NOTHING! Time to face reality. Nothing to see here. 

[Angler101]

13X2413000000000......You're right.....time to sell both your shares and invest elsewhere.....see ya

[13X2413]

Aren't you worried that if I sell both of my shares, it'll knock it down below a dollar?

[Angler101]

No, but I am worried that you'll be lonely, because we're probably the only friends you have.

[Noteable]

Great News on what the FDA considers the primary clinical benefit for an Accelerated Approval of a drug, that of overall survival (OS). Today's press release demonstrated that Bracelet-1 two (2) year median overall survival (mOS) (24 months) for the pelareeorep + paclitaxel treatment cohort was near 2X over the control group (paclitaxel alone) and the long term OS continues to mature. These

[Noteable]

Another giant step towards pelareorep's potential Accelerated Approval. In 2022, approximately 604,900 women were diagnosed with breast cancer in the WHO Europe region. Incidence in the EU-27 in 2022 was estimated to be 375,000 Therefore approximately 243,000 mBC patients would be diagnosed with HR+/HER2- in the EU-27, for example. Of this conservative number

[Noteable]

Somebody from ONCY needs to step up their responsibilites in knocking down Big Pharma's door.

[fasttrack5]

Actually one would think that big Pharma  would be knocking on their door.  Just sayin:)

[laroplex]

Totally agree 100%....It seems they are trying to milk their salaries...Don't get me wrong i'm totally attached to T.ONC, love this company, but management are useless lately....When i read the n/r didn't get off on how they phrase  their heading....Great news but to new investors, it seems like nah not  the best, yet it's fantastic news.....The life in ONCY's world

[jh1970]

Institustions and Big Pharmas understand very well this news . They probably had knowlege some time ago. They know that company needs money. Financing is coming.

[Noteable]

This kind of positive news on long-term results generally results in a deal, $$ generating partnership, an acquisition, or non-dilutive financing (as the extreme of an ineffective management).

[Buckhenry]

I feel so much better unnoteable telling us a deal is imminent... for the thousandth  time... geez

[Noteable]

Learn to read Buckeroo .... I repeated what Kirk Look said last week, which was the Bracelet-1 OS results were imminent. And those results were released today, which was as close to imminent as one would expect. And if a deal is imminent, then I would like to hear that from Kirk Look as well.

[CMHarring218431]

IMHO I don't think a deal is imminent, simply because the headline implies that with these clinical results, we are now in a better position to secure financing. As a negotiating tool, maybe it is just a way of saying we can fund our portion of a partnership 

[Noteable]

Kirk Look's presentation at Cantor's Global Healthcare Conference was less than stellar. More properly described as DULL and lacking energy. Christope Degois and Thomas Heineman were no better.